Trial record 1 of 3 for:    cubist | Exclude Unknown | diarrhea
Previous Study | Return to List | Next Study

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

This study is currently recruiting participants.
Verified April 2014 by Cubist Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01597505
First received: May 10, 2012
Last updated: April 8, 2014
Last verified: April 2014
  Purpose

608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.


Condition Intervention Phase
Clostridium Difficile Infection
Drug: CB-183,315
Drug: oral vancomycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Resource links provided by NLM:


Further study details as provided by Cubist Pharmaceuticals:

Primary Outcome Measures:
  • The proportion of subjects with a clinical outcome of cure [ Time Frame: Two days after last dose of study drug ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The clinical response over time based on the length of time it takes for the subjects to fail treatment, recur, die, or become lost to follow-up until Day 40 [ Time Frame: 30 days after the last dose of study drug ] [ Designated as safety issue: No ]
  • The proportion of subjects who sustain a clinical outcome of cure until Day 50 [ Time Frame: 30 days after last dose of study drug ] [ Designated as safety issue: No ]

Estimated Enrollment: 608
Study Start Date: May 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CB-183,315 250mg/Surotomycin Drug: CB-183,315
250 mg bid for 10 days
Other Name: Surotomycin
Active Comparator: oral vancomycin, 125 mg Drug: oral vancomycin
oral, 125 mg qid for 10 days

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

To be included in this study, participants must:

  • Sign a consent form;
  • Be older 18 or older and 90 or younger;
  • Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
  • Test positive for Clostridium difficile;
  • If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.

Participants will not be allowed into the study if they:

  • Have toxic megacolon and/or known small bowel ileus;
  • Have received treatment with intravenous immune globulin (IVIG)within the past 30 days;
  • Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
  • Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
  • Have received an investigational vaccine against C. difficile;
  • Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
  • Had more than 2 episodes of CDAD within 90 days;
  • Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months(this does not include appendectomy or cholecystectomy);
  • Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
  • Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
  • Are unable to discontinue opiate treatment unless on a stable dose;
  • Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
  • Had stool studies positive for pathogenic ova and/or parasites;
  • Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;
  • Have life-threatening illness at the time of enrollment;
  • Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
  • Have received an investigational drug or participated in any experimental procedure within 1 month;
  • Have HIV, a CD4 < 200 cells/mm3 within 6 months of start of study therapy;
  • Anticipate that certain antibacterial therapy for a non-CDAD infection will be required for > 7 days;
  • Are unable to discontinue Saccharomyces or similar probiotic;
  • Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
  • Are unable to comply with the protocol requirements;
  • Have any condition that, in the opinion of the Investigator, might interfere;
  • Are not expected to live for less than 8 weeks.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01597505

Contacts
Contact: Mary E Sweeney 6102392764 mary.sweeney@incresearch.com
Contact: Julie Donovan 7818608162 julie.donovan@cubist.com

  Hide Study Locations
Locations
United States, Arizona
Terminated
Phoenix, Arizona, United States
Recruiting
Phoenix, Arizona, United States
United States, Arkansas
Terminated
Little Rock, Arkansas, United States
Recruiting
Little Rock, Arkansas, United States
United States, California
Recruiting
Colton, California, United States
Terminated
Escondido, California, United States
Terminated
Long Beach, California, United States
Terminated
Los Angeles, California, United States
Recruiting
Modesto, California, United States
Recruiting
San Diego, California, United States
United States, Colorado
Recruiting
Lafayette, Colorado, United States
United States, Florida
Recruiting
Aventura, Florida, United States
Recruiting
Clearwater, Florida, United States
Terminated
Miami, Florida, United States
Recruiting
Naples, Florida, United States
Recruiting
Port Orange, Florida, United States
Recruiting
Tampa, Florida, United States
Terminated
Zephyrhills, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Recruiting
Augusta, Georgia, United States
Recruiting
Savannah, Georgia, United States
United States, Illinois
Recruiting
Carbondale, Illinois, United States
Recruiting
Chicago, Illinois, United States
Recruiting
Springfield, Illinois, United States
Recruiting
Urbana, Illinois, United States
United States, Indiana
Terminated
Indianapolis, Indiana, United States
United States, Kentucky
Terminated
Louisville, Kentucky, United States
United States, Louisiana
Recruiting
New Orleans, Louisiana, United States
United States, Maryland
Recruiting
Annandale, Maryland, United States
Recruiting
Annapolis, Maryland, United States
Terminated
Baltimore, Maryland, United States
Recruiting
Baltimore, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
Terminated
Brockton, Massachusetts, United States
Recruiting
West Roxbury, Massachusetts, United States
Terminated
Worcester, Massachusetts, United States
United States, Michigan
Recruiting
Detriot, Michigan, United States
United States, Minnesota
Recruiting
Minneapolis, Minnesota, United States
United States, Missouri
Terminated
Mexico, Missouri, United States
United States, Montana
Recruiting
Butte, Montana, United States
United States, New Jersey
Recruiting
Hackensack, New Jersey, United States
United States, New York
Recruiting
Bronx, New York, United States
Recruiting
Buffalo, New York, United States
Recruiting
Jamaica Queens, New York, United States
Recruiting
New York, New York, United States
Recruiting
Poughkeepsie, New York, United States
Recruiting
Rochester, New York, United States
Recruiting
Syracuse, New York, United States
United States, North Carolina
Terminated
Winston Salem, North Carolina, United States
Recruiting
Winston-Salem, North Carolina, United States
United States, North Dakota
Recruiting
Bismark, North Dakota, United States
Recruiting
Fargo, North Dakota, United States
United States, Ohio
Terminated
Akron, Ohio, United States
Recruiting
Cleveland, Ohio, United States
Recruiting
Columbus, Ohio, United States
Recruiting
Mentor, Ohio, United States
Recruiting
Middleburg Heights, Ohio, United States
Recruiting
Toledo, Ohio, United States
United States, Pennsylvania
Terminated
Philadelphia, Pennsylvania, United States
Terminated
Sellersville, Pennsylvania, United States
United States, Tennessee
Terminated
Kingsport, Tennessee, United States
Terminated
Mountain Home, Tennessee, United States
United States, Texas
Terminated
Dallas, Texas, United States
Terminated
San Antonio, Texas, United States
United States, Utah
Recruiting
Salt Lake City, Utah, United States
Austria
Recruiting
Feldkirch, Austria
Recruiting
Graz, Austria
Recruiting
Innsbruck, Austria
Recruiting
Salzburg, Austria
Recruiting
St. Poelten, Austria
Recruiting
Vienna, Austria
Belgium
Recruiting
Bruxelles, Belgium
Recruiting
Charleroi, Belgium
Recruiting
Ghent, Belgium
Canada, Alberta
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Canada, Manitoba
Recruiting
Winnepeg, Manitoba, Canada
Canada, Ontario
Recruiting
Hamilton, Ontario, Canada
Recruiting
Oshawa, Ontario, Canada
Canada, Quebec
Recruiting
Chicoutimi, Quebec, Canada
Recruiting
Quebec City, Quebec, Canada
Recruiting
St. Jerome, Quebec, Canada
Czech Republic
Recruiting
Brno, Czech Republic
Recruiting
Hradec Kralove, Czech Republic
Recruiting
Kolin, Czech Republic
Recruiting
Kromeriz, Czech Republic
Recruiting
Melnik, Czech Republic
Recruiting
Opava, Czech Republic
Recruiting
Pardubice, Czech Republic
Recruiting
Plzen, Czech Republic
Recruiting
Praha, Czech Republic
France
Recruiting
Paris, France
Recruiting
Pringy, France
Recruiting
Rennes, France
Recruiting
Tourcoing, France
Recruiting
Tours, France
Germany
Recruiting
Augsburg, Germany
Recruiting
Berlin, Germany
Recruiting
Bochum, Germany
Recruiting
Chorzow, Germany
Recruiting
Heidelberg, Germany
Recruiting
Jena, Germany
Recruiting
Koln, Germany
Recruiting
Leipzig, Germany
Recruiting
Lubeck, Germany
Recruiting
Magdeburg, Germany
Recruiting
Mainz, Germany
Recruiting
Marburg, Germany
Recruiting
Munich, Germany
Recruiting
Potsdam, Germany
Recruiting
Rostock, Germany
Recruiting
Tuebingen, Germany
Recruiting
Ulm, Germany
Recruiting
Wurzburg, Germany
Hungary
Recruiting
Budapest, Hungary
Recruiting
Debrecen, Hungary
Recruiting
Miskolc, Hungary
Recruiting
Pecs, Hungary
Israel
Recruiting
Bnai-Zion, Israel
Recruiting
Tel-Aviv, Israel
Recruiting
Zefat, Israel
Recruiting
Zrifin Beer-Yaakov, Israel
Italy
Recruiting
Bagno A Ripole, Italy
Recruiting
Bologna, Italy
Recruiting
Busto Arsizio, Italy
Recruiting
Cremona, Italy
Recruiting
Firenze, Italy
Recruiting
Lecco, Italy
Recruiting
Milano, Italy
Recruiting
Modena, Italy
Recruiting
Pavia, Italy
Recruiting
San Donato Milanese, Italy
Poland
Recruiting
Bialystock, Poland
Recruiting
Bydgoszcz, Poland
Recruiting
Chorzow, Poland
Terminated
Ciechanow, Poland
Recruiting
Lancut, Poland
Recruiting
Lodz, Poland
Terminated
Lublin, Poland
Recruiting
Pulawy, Poland
Terminated
Radom, Poland
Terminated
Sopot, Poland
Recruiting
Warsaw, Poland
Recruiting
Wroclaw, Poland
Spain
Recruiting
Alicante, Spain
Recruiting
Barcelona, Spain
Recruiting
Granada, Spain
Recruiting
Madrid, Spain
Recruiting
Majadahonda, Spain
Recruiting
Mataro, Spain
Recruiting
Reus, Spain
Recruiting
San Sebastian, Spain
Recruiting
Terrassa, Spain
Sweden
Recruiting
Linkoping, Sweden
Recruiting
Stockholm, Sweden
Recruiting
Uppsala, Sweden
United Kingdom
Recruiting
Blackpool, United Kingdom
Recruiting
Hull, East Yorkshire, United Kingdom
Recruiting
Leicester, United Kingdom
Recruiting
London, United Kingdom
Recruiting
Middlesex, United Kingdom
Recruiting
Norwich, United Kingdom
Recruiting
Sheffield, United Kingdom
Sponsors and Collaborators
Cubist Pharmaceuticals
Investigators
Study Director: Hernando Patino, MD Cubist Pharmaceuticals Medical Monitor
  More Information

No publications provided

Responsible Party: Cubist Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01597505     History of Changes
Other Study ID Numbers: LCD-CDAD-10-07
Study First Received: May 10, 2012
Last Updated: April 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cubist Pharmaceuticals:
CDAD
Clostridium difficile Associated Diarrhea
CDI
Clostridium difficile Infection
Diarrhea

Additional relevant MeSH terms:
Diarrhea
Clostridium Infections
Signs and Symptoms, Digestive
Signs and Symptoms
Gram-Positive Bacterial Infections
Bacterial Infections
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 20, 2014